Erectile dysfunction and cardiovascular considerations: managing patients effectively with phosphodiesterase type 5 inhibitors.
Hutter
Adolph M
AM
Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA.
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy; D000075202:Contraindications; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004334:Drug Administration Schedule; D004347:Drug Interactions; D007172:Erectile Dysfunction / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009566:Nitrates / Q000008:administration & dosage; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*
D009566:Nitrates; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human